Compare Novartis AG (NVS) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Plby Group Inc — how do they compare? Novartis AG trades at $153.29 (market cap $295.37B), while Plby Group Inc trades at $1.31 (market cap $162.94M). The key difference: Novartis AG is far larger — about 1812.8× Plby Group Inc's market cap, and Novartis AG pays a 3.07% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| NVS | PLBY | |
|---|---|---|
Market Cap | $295.37B | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $2.71 |
52-Week Low | $119.31 | $1.11 |
Enterprise Value | $336.69B | $308.52M |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
PLBY trades at $1.18, down 3.28% recently, with a bearish technical signal. The company reported Q2 2026 revenue growth and positive operating cash flow, with net income turning positive in 2026 after years of losses. Valuation ratios like P/E of 68 and P/S of 1.2 appear elevated relative to profitability. Recent news highlights inclusion in Russell indexes and leadership expansion.
The outlook is cautiously optimistic with improving fundamentals, but high debt and thin margins pose risks. Analyst consensus is strongly bullish with 75% buy ratings, yet the stock faces execution risks in licensing growth and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
